Colossal Biosciences: 2025 TIME100 Most Influential CompaniesExtinction ain’t what it used to be. Around one-third of all existing species could vanish due to global warming by 2050 according to ...

Forte Biosciences (FBRX) announces public offering of stock & pre-funded warrants. Funds to fuel R&D, clinical trials & operations.

HYDERABAD: A Union government-appointed inspection committee has recommended immediate regulatory action, including the removal and rehabilitation of over 1,200 animals from Palamur Biosciences in ...

11 analysts have expressed a variety of opinions on Avidity Biosciences RNA over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a snapshot ...

By Denny Jacob Ventyx Biosciences disclosed positive top-line results from its Phase 2a study of VTX3232 in patients with early-stage Parkinson's disease.

LifT Biosciences leases lab space at Texas Medical Center's Helix Park, expanding its innovative cancer immunotherapy research to the U.S.

Forte Biosciences (NASDAQ:FBRX) has announced the pricing of its public offering of 5,630,450 shares of common stock at $12.00 per share, for an expected gross proceeds to be approximately $75 ...

CAMBRIDGE, Mass., June 16, 2025--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule ...

DALLAS-- (BUSINESS WIRE)-- Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of ...